Filing Flows › Health Care › Immunome (IMNM)
Immunome (IMNM) earnings and revenue breakdown
Latest: Q2 2025 · 10-Q filed Aug 6, 2025 · Immunome (IMNM) Q2 2025 earnings results →
Q2 2025 Revenue up 70% year over year to $4.0M
Immunome made $4.0M in Q2 2025 (+70% Y/Y). Operating margin n/m, net loss $43.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.0M in Q2 2025, up 70% year over year and up 37% from the previous quarter.
Operating costs exceeded revenue by $46.5M, an operating margin of -1157.6%. Total costs grew 19% against revenue growth of 70%. The fastest-growing cost line was General & admin (+44%). The quarter ended with a net loss of $43.4M, wider than the previous quarter's $41.6M loss.
Operating cash flow was −$49.4M. Non-cash charges added back $637K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $12.0M. Capital expenditures of $905K exceeded it, leaving free cash flow of −$50.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2025 | 10-Q | Aug 6, 2025 | $4.0M | +70% | n/m | −$43.4M | −$49.4M |
| Q1 2025 | 10-Q | May 12, 2025 | $2.9M | +184% | n/m | −$41.6M | −$53.1M |
| Q4 2024 | 10-K | Mar 19, 2025 | $2.7M | -28% | n/m | −$80.2M | −$42.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Immunome
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics. We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an investigational, oral, once-daily gamma secretase inhibitor, or GSI. In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. We anticipate submitting a new drug application, or NDA, in the second quarter of 2026.
In its own words, from its 10-K, filed Mar 3, 2026.
Immunome against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +70% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IMNM Immunome | Q2 2025 | $4.0M | +70% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Immunome 10-Q on SEC EDGAR · CIK 1472012 · Pharmaceutical Preparations
13F: who owns IMNM and who is buying
More on IMNM
History
Every quarter: Q2 2025 results · Q1 2025 results · Q4 2024 results